Core Viewpoint - The company has reported significant asset impairment provisions for the first half of 2025, reflecting a cautious approach to its financial reporting and asset management [5][6][7]. Group 1: Company Overview - The company is identified as 起步股份有限公司 (ST Qibu) with the stock code 603557 [1]. - The board of directors and supervisory board members have confirmed the authenticity and completeness of the financial report [1][4]. Group 2: Financial Data - The company has recognized a total asset impairment loss of 41,561,706.09 yuan for the first half of 2025, which includes 22,098,006.19 yuan for inventory and 19,463,699.90 yuan for credit impairment losses [6][7]. - Specific credit impairment losses include 18,916,787.81 yuan for accounts receivable and 546,912.09 yuan for other receivables [6]. Group 3: Asset Impairment Provisions - The board's audit committee has deemed the asset impairment provisions to be reasonable and in accordance with accounting standards [8]. - The supervisory board has also agreed that the provisions align with relevant policies and accurately reflect the company's asset value [9]. Group 4: Fundraising and Usage - The company raised 520 million yuan through convertible bonds, with a net amount of 509.1976 million yuan after expenses [14]. - As of June 30, 2025, the company had four fundraising accounts, with no idle funds being used for cash management during the first half of 2025 [22][27]. Group 5: Project Updates - The "Baby and Children's Products Sales Network Construction Project" has been delayed for over a year, with planned investments of 35,072.09 million yuan, of which 18,957.56 million yuan is expected to be funded from the raised capital [28][29]. - The "Smart Information System Upgrade Project" has also seen slow progress, with only 2,332.60 million yuan of the planned 17 million yuan utilized as of June 30, 2025 [29][30].

Core Viewpoint - The report outlines the fundraising activities and management of Hubei Wanrun New Energy Technology Co., Ltd., detailing the total amount raised, the usage of funds, and the company's compliance with regulatory requirements [4][26][46]. Group 1: Fundraising Overview - The company raised a total of RMB 638,858.20 million through the issuance of 21,303,795 shares at a price of RMB 299.88 per share, with a net amount of RMB 614,562.26 million after deducting issuance costs [4][26]. - As of June 30, 2025, the company had utilized RMB 593,293.73 million of the raised funds, leaving RMB 28,654.61 million unutilized [6][10]. Group 2: Fund Management - The company has established special accounts for the management of raised funds, ensuring compliance with relevant laws and regulations [7][25]. - A tripartite supervision agreement was signed with banks and the sponsor to oversee the management of the raised funds [7][8]. Group 3: Fund Usage - The company has invested RMB 579,860.75 million in related projects, excluding the permanent replenishment of working capital from surplus funds [10][15]. - Surplus funds from the "Hongmai High-tech High-performance Lithium-ion Battery Material Project" amounting to RMB 13,432.98 million have been permanently allocated to replenish working capital [15][19]. Group 4: Cash Management - The company plans to use up to RMB 20,000.00 million of temporarily idle raised funds for cash management, focusing on safe and liquid investment products [23][32]. - The cash management strategy aims to enhance the efficiency of fund usage while ensuring that it does not affect the progress of investment projects [37][48]. Group 5: Compliance and Oversight - The supervisory board has confirmed that the company adheres to all relevant regulations regarding the management and usage of raised funds, ensuring no harm to shareholder interests [46][48]. - The sponsor has also provided a no-objection opinion regarding the cash management proposal, affirming its compliance with regulatory requirements [40][48].

Fundraising Overview - The company raised a total of RMB 250,185,200.00 from the issuance of 26.17 million shares at a price of RMB 9.56 per share, with a net amount of RMB 201,657,254.21 after deducting fees [1][17] - As of June 30, 2025, the company has utilized RMB 104,341,832.65 of the raised funds, including RMB 12,380,387.06 from self-raised funds and RMB 91,961,445.59 directly from the raised funds [2] - The remaining balance in the fundraising account is RMB 71,816,631.64 [2] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure the proper management and use of the raised funds [2] - The company signed a tripartite supervision agreement with the underwriting institution and the bank holding the fundraising account to clarify the rights and obligations of all parties involved [3] Fund Usage and Returns - The company temporarily used RMB 1,700,000 of idle funds to supplement working capital, which has been fully returned to the fundraising account as of April 3, 2025 [6] - An additional temporary use of up to RMB 2,000,000 of idle funds for working capital was approved, with a return deadline of 12 months [7] - The company has engaged in cash management with idle funds, with a total rolling amount of RMB 13,300,000, yielding a total return of RMB 25,840.00 [9] Project Updates - The company has decided to extend the timeline for the "Magnetic Resistance Motor Industrial Base Project" to June 2027 after re-evaluating its feasibility [12] - The deadlines for the "Smart Grid Fault Monitoring and Automation Product Upgrade Project" and "Modern Electrical Automation Technology Research Institute Construction Project" have been extended to December 2025 [12] Asset Impairment - The company has recognized a total asset impairment provision of RMB 3,624,100.00 for the first half of 2025, which includes credit impairment losses and inventory write-downs [21][26] - The impairment provisions were approved by the audit committee and the board of directors, ensuring compliance with accounting standards [28][29]

Group 1 - The company raised a total of approximately RMB 500 million through a specific stock issuance, with a net amount of approximately RMB 485.54 million after deducting issuance costs [2][3] - The issuance was approved by the China Securities Regulatory Commission on December 4, 2023, and the shares were priced at RMB 7.12 each [2] - The funds raised are intended for various projects, including replacing self-raised funds and supplementing working capital [3][4] Group 2 - As of June 30, 2025, the company had utilized approximately RMB 122,500 for a high-purity phosphoric acid project and temporarily supplemented working capital with idle funds amounting to approximately RMB 197.29 million [4][6] - The remaining balance in the fundraising account as of June 30, 2025, was approximately RMB 6.82 million [4] Group 3 - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure proper use and management of the raised funds [5][6] - The company has signed tripartite and quadripartite agreements with its subsidiaries and underwriters to ensure strict approval procedures for fund usage [6] Group 4 - There have been no changes to the fundraising investment projects or any transfers or replacements of these projects [8] - The company has disclosed all information regarding the use of raised funds in a timely and accurate manner, with no violations reported [9] Group 5 - The company reported a net profit of approximately RMB 456.55 million for the first half of 2025, with a proposed cash dividend of RMB 1.60 per 10 shares [75] - The total cash dividend is expected to amount to approximately RMB 154.74 million, with no stock dividends or capital reserve transfers planned [75] Group 6 - The company held its 24th meeting of the 8th Board of Directors on August 28, 2025, where several governance documents were revised and approved [71][79] - The company plans to hold its third extraordinary general meeting of 2025 on September 15, 2025, to discuss various proposals [79]

Fundraising Overview - The company raised a total of RMB 980,784,000.00 from the issuance of 33,600,000 shares at a price of RMB 29.19 per share, with a net amount of RMB 891,810,577.60 after deducting underwriting and other issuance costs [1][2] - The actual amount received was RMB 914,129,120.00, which includes untransferred issuance costs of RMB 22,318,542.40 [1] Fund Usage and Balance - As of June 30, 2025, the company has utilized RMB 493,741,885.22 of the raised funds and has replaced RMB 15,944,203.02 for issuance costs [2] - The balance in the fundraising account was RMB 172,181,185.10, with RMB 270,000,000.00 in cash management products that have not yet matured [2][6] Fund Management - The company has established a fundraising management system to ensure proper use and management of the funds, in compliance with relevant regulations [3] - A tripartite supervision agreement was signed with several banks to clarify the rights and obligations of all parties involved in the management of the funds [3] Investment Projects - The company has not used self-raised funds for pre-investment in fundraising projects during the reporting period [5] - There were no instances of using idle funds to supplement working capital [5] Cash Management - The company has approved the use of up to RMB 586,000,000.00 of temporarily idle funds for cash management, with a focus on high-security and liquid investment products [5] - As of June 30, 2025, the total investment income from cash management was RMB 367,676.58 [6] Use of Over-raised Funds - The company has used RMB 53,462,956.35 of over-raised funds to permanently supplement working capital, with a similar amount of RMB 37,000,000.00 approved later [7][8] - By June 30, 2025, a total of RMB 142,553,400.00 of over-raised funds has been used for this purpose [9] Project Adjustments - The company has postponed the expected usable status date for certain fundraising projects to July 1, 2026, as approved in board meetings [12] Compliance and Reporting - The company has adhered to all relevant laws and regulations regarding the use of raised funds and has disclosed information accurately and timely [13][23]

Fundraising Overview - The company raised a total of RMB 1,308,240,000.00 from its initial public offering (IPO) in 2020, with a net amount of RMB 1,209,126,994.80 after deducting issuance costs [1] - In 2023, the company issued 94,307,847 shares at a price of RMB 29.69 per share, raising RMB 2,799,999,977.43, with a net amount of RMB 2,789,610,146.80 after costs [2] Fund Utilization - As of June 30, 2025, the company had utilized RMB 1,172,663,582.49 from the 2020 IPO funds, with a remaining balance of RMB 44,861,956.18 [2][3] - For the 2023 fundraising, RMB 1,681,031,283.03 has been used, leaving a balance of RMB 1,140,447,626.44, which includes RMB 500,000,000.00 temporarily used for working capital [3][4] Fund Management - The company has established a fundraising management system in compliance with regulations, ensuring funds are stored in dedicated accounts and used strictly for designated purposes [4][6] - A tripartite supervision agreement was signed with the underwriter and banks for both the 2020 IPO and the 2023 fundraising, ensuring proper management of the funds [4][6] Project Completion and Fund Reallocation - The project funded by the 2020 IPO for producing 80,000 aviation tires has been completed, and surplus funds have been permanently allocated to working capital [5][16] - The company has also approved the reallocation of funds from the 2023 fundraising to new projects in Morocco, changing the original project focus [18][19] Profit Distribution Proposal - The company proposed a cash dividend of RMB 3.00 per 10 shares for the first half of 2025, amounting to a total of RMB 310,732,772.40 based on the current share count [24][25] - This proposal is based on the company's strong financial performance, with a net profit of RMB 661,655,309.50 for the first half of 2025 [24]

Fundraising Overview - The company raised a total of RMB 20 million through the issuance of 2 million convertible bonds at a face value of RMB 100 each, with a net amount of RMB 19.31 million available after deducting issuance costs of RMB 0.69 million [1] - As of June 30, 2025, the company has utilized RMB 19.70 million of the raised funds, leaving a balance of RMB 0 [1] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations, ensuring the funds are stored in dedicated bank accounts and managed under a tripartite supervision agreement with the underwriter and banks [2][3] - As of June 30, 2025, the company had three dedicated fundraising accounts, which were closed after transferring the remaining funds and interest to the company's general account [3] Fund Usage - In the first half of 2025, the company used RMB 9.03 million of the raised funds, with RMB 0.57 million allocated to investment projects and RMB 8.97 million supplementing working capital after the termination of the investment project [1] - The company approved the use of RMB 6.57 million of the raised funds to replace self-raised funds previously invested in projects, which was verified by an accounting firm [5] Temporary Fund Supplementation - The company temporarily supplemented working capital with idle raised funds, approving up to RMB 3.30 million and later RMB 5.50 million, both of which were fully returned to the dedicated accounts by June 26, 2025 [6] Project Changes - The company terminated the "Annual Production of 2400 Tons of Multifunctional, High-Performance High-Strength High-Modulus Polyethylene Fiber Project" and decided to permanently supplement the remaining funds into working capital [11] Compliance and Reporting - The company has adhered to regulations regarding the management and disclosure of raised funds, ensuring timely and accurate reporting without any violations [14]

证券代码：688271 证券简称：联影医疗 公告编号：2025-037 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 根据《上市公司募集资金监管规则》《上海证券交易所科创板上市公司自律监管指引第1号——规范运 作》等相关规定，上海联影医疗科技股份有限公司（以下简称"公司"或"联影医疗"）将公司2025年半年 度募集资金存放与实际使用情况专项报告如下： 一、募集资金基本情况 根据中国证监会核发的《关于同意上海联影医疗科技股份有限公司首次公开发行股票注册的批复》（证 监许可[2022]1327号），公司获准向社会公开发行人民币普通股（A股）10,000万股，发行价格为人民 币109.88元/股，募集资金总额人民币1,098,800万元。公司募集资金总额扣除所有股票发行费用（包括 不含增值税的承销及保荐费用以及其他发行费用）人民币264,158,460.63元后的募集资金净额为人民币 10,723,841,539.37元。上述募集资金到位情况业经普华永道中天会计师事务所（特殊普通合伙）审验， 并出具了普华永道中天验字（2022 ...

Fundraising Overview - The company raised a total of RMB 1,840,000,000.00 from the issuance of 20,000,000 shares at a price of RMB 92.00 per share, with net proceeds after fees amounting to RMB 1,671,699,800.72 [1][2] - The funds were verified by Lixin Certified Public Accountants [2] Fund Usage and Management - As of June 30, 2025, the company has established a dedicated account for the management of the raised funds, ensuring compliance with relevant regulations [4][5] - The company has not used idle funds for temporary working capital during the reporting period [6][9] - The company has approved the use of up to RMB 12 billion of temporarily idle funds for cash management, ensuring that it does not affect project construction or fund safety [7][8] Changes in Fund Allocation - The company has adjusted the internal investment structure and implementation content of its fundraising projects, specifically for the "Vehicle Ethernet Chip Development and Industrialization Project" and the "Research and Development Center Construction Project" [12][13] - The company has utilized RMB 12,213.35 million of self-raised funds for project expenses, which will be replaced by the raised funds later [11] Compliance and Reporting - The company has confirmed that there are no issues with the disclosure of fundraising information, and all management practices comply with regulations [13][21] - The supervisory board has approved the half-year report and the special report on the storage and actual use of raised funds, affirming that the information is accurate and complete [20][22] Upcoming Investor Interaction - The company will participate in a collective performance briefing for the chip design industry on September 8, 2025, to address investor inquiries regarding its half-year performance [24][25]

Core Points - The company Shanghai Hejing Silicon Materials Co., Ltd. has reported on the status of its fundraising activities for the first half of 2025, confirming compliance with relevant regulations and the proper management of raised funds [1][12]. Fundraising Overview - The company issued 66,206,036 shares at a price of 22.66 RMB per share, raising a total of approximately 1.5 billion RMB, with a net amount of about 1.39 billion RMB after deducting issuance costs [1]. - As of June 30, 2025, the company has utilized approximately 868.68 million RMB of the raised funds, leaving a balance of about 537.75 million RMB [2]. Fund Management - The company has established a fundraising management system to ensure the safety and proper use of the raised funds, in accordance with the Shanghai Stock Exchange regulations [2]. - A tripartite supervision agreement has been signed with banks to oversee the management of the fundraising account, ensuring compliance with legal requirements [3]. Cash Management - The company has approved the use of up to 735 million RMB of temporarily idle funds for cash management, focusing on low-risk, high-liquidity financial products [5]. - As of June 30, 2025, the balance of idle funds under cash management was approximately 482.55 million RMB [6]. Fund Usage and Adjustments - There were no instances of using idle funds to temporarily supplement working capital during the reporting period [6]. - The company has not made any changes to the fundraising projects or reported any surplus funds as of June 30, 2025 [11][7]. Project Delays - The timeline for the "High-Quality Epitaxial Wafer R&D and Industrialization Project" has been extended to December 2026 due to market demand changes [10].